HRP20171080T1 - Protutijela s modificiranim affinitetom za fcrn koja potiču uklanjanje antigena - Google Patents

Protutijela s modificiranim affinitetom za fcrn koja potiču uklanjanje antigena Download PDF

Info

Publication number
HRP20171080T1
HRP20171080T1 HRP20171080TT HRP20171080T HRP20171080T1 HR P20171080 T1 HRP20171080 T1 HR P20171080T1 HR P20171080T T HRP20171080T T HR P20171080TT HR P20171080 T HRP20171080 T HR P20171080T HR P20171080 T1 HRP20171080 T1 HR P20171080T1
Authority
HR
Croatia
Prior art keywords
amino acid
ala
instead
acid substitutions
antibody
Prior art date
Application number
HRP20171080TT
Other languages
English (en)
Inventor
Tomoyuki Igawa
Shinya Ishii
Atsuhiko Maeda
Takashi Nakai
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44260244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171080(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of HRP20171080T1 publication Critical patent/HRP20171080T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Claims (14)

1. Protutijelo, naznačeno time što sadrži domenu za vezanje na antigen i domenu za vezanje na ljudski FcRn, koja ima aktivnost vezanja na ljudski FcRn kod pH 5,5 i kod pH 7,0 i manju aktivnost vezanja na antigen kod pH 5,5 nego kod pH 7,0, gdje je aktivnost vezanja na ljudski FcRn kod pH 7,0 i na 25 °C veća nego KD 3,2 mM, gdje je domena za vezanje na ljudski FcRn Fc domena dobivena zamjenom različite aminokiselina umjesto najmanje jedne aminokiseline u Fc domeni ljudskog IgG1, IgG2, IgG3 ili IgG4.
2. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što je omjer između aktivnosti vezanja na antigen kod pH 5,5 i kod pH 7,0 najmanje 2 u vrijednosti KD (kod pH 5,5)/KD (kod pH 7,0).
3. Protutijelo u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što sadrži aminokiselinsku mutaciju u domeni za vezanje na antigen, koja se sastoji u zamjeni histidinom najmanje jedne aminokiseline u domeni za vezanje na antigen ili ubacivanju najmanje jednog histidina.
4. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što se domena za vezanje na antigen dobiva iz biblioteke domena za vezanje na antigen.
5. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačeno time što je domena za vezanje na ljudski FcRn domena za vezanje na ljudski FcRn koja sadrži aminokiselinski slijed sa zamjenom različitom aminokiselinom umjesto najmanje jedne aminokiseline koja se bira između onih na položajima 237, 238, 239, 248, 250, 252, 254, 255, 256, 257, 258, 265, 270, 286, 289, 297, 298, 303, 305, 307, 308, 309, 311, 312, 314, 315, 317, 325, 332, 334, 360, 376, 380, 382, 384, 385, 386, 387, 389, 424, 428, 433, 434, te 436 (EU numeriranje) u Fc domeni ljudskog IgG1, IgG2, IgG3 ili IgG4.
6. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačeno time što sadrži domenu za vezanje na ljudski FcRn koja sadrži aminokiselinsku zamjenu u Fc domeni ljudskog IgG1, IgG2, IgG3 ili IgG4, koja sadrži najmanje jednu aminokiselinsku zamjenu koju se bira između: aminokiselinske zamjene Met umjesto Gly na položaju 237; aminokiselinske zamjene Ala umjesto Pro na položaju 238; aminokiselinske zamjene Lys umjesto Ser na položaju 239; aminokiselinske zamjene Ile umjesto Lys na položaju 248; aminokiselinske zamjene Ala, Phe, Ile, Met, Gln, Ser, Val, Trp ili Tyr umjesto Thr na položaju 250; aminokiselinske zamjene Phe, Trp ili Tyr umjesto Met na položaju 252; aminokiselinske zamjene Thr umjesto Ser na položaju 254; aminokiselinske zamjene Glu umjesto Arg na položaju 255; aminokiselinske zamjene Asp, Glu ili Gln umjesto Thr na položaju 256; aminokiselinske zamjene Ala, Gly, He, Leu, Met, Asn, Ser, Thr ili Val umjesto Pro na položaju 257; aminokiselinske zamjene His umjesto Glu na položaju 258; aminokiselinske zamjene Ala umjesto Asp na položaju 265; aminokiselinske zamjene Phe umjesto Asp na položaju 270; aminokiselinske zamjene Ala, ili Glu umjesto Asn na položaju 286; aminokiselinske zamjene His umjesto Thr na položaju 289; aminokiselinske zamjene Ala umjesto Asn na položaju 297; aminokiselinske zamjene Gly umjesto Ser na položaju 298; aminokiselinske zamjene Ala umjesto Val na položaju 303; aminokiselinske zamjene Ala umjesto Val na položaju 305; aminokiselinske zamjene Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Val, Trp ili Tyr umjesto Thr na položaju 307; aminokiselinske zamjene Ala, Phe, Ile, Leu, Met, Pro, Gln ili Thr umjesto Val na položaju 308; aminokiselinske zamjene Ala, Asp, Glu, Pro ili Arg umjesto Leu ili Val na položaju 309; aminokiselinske zamjene Ala, His ili Ile umjesto Gln na položaju 311; aminokiselinske zamjene Ala ili His umjesto Asp na položaju 312; aminokiselinske zamjene Lys ili Arg umjesto Leu na položaju 314; aminokiselinske zamjene Ala ili His umjesto Asn na položaju 315; aminokiselinske zamjene Ala umjesto Lys na položaju 317; aminokiselinske zamjene Gly umjesto Asn na položaju 325; aminokiselinske zamjene Val umjesto Ile na položaju 332; aminokiselinske zamjene Leu umjesto Lys na položaju 334; aminokiselinske zamjene His umjesto Lys na položaju 360; aminokiselinske zamjene Ala umjesto Asp na položaju 376; aminokiselinske zamjene Ala umjesto Glu na položaju 380; aminokiselinske zamjene Ala umjesto Glu na položaju 382; aminokiselinske zamjene Ala umjesto Asn ili Ser na položaju 384; aminokiselinske zamjene Asp ili His umjesto Gly na položaju 385; aminokiselinske zamjene Pro umjesto Gln na položaju 386; aminokiselinske zamjene Glu umjesto Pro na položaju 387; aminokiselinske zamjene Ala ili Ser umjesto Asn na položaju 389; aminokiselinske zamjene Ala umjesto Ser na položaju 424; aminokiselinske zamjene Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Asn, Pro, Gln, Ser, Thr, Val, Trp ili Tyr umjesto Met na položaju 428; aminokiselinske zamjene Lys umjesto His na položaju 433; aminokiselinske zamjene Ala, Phe, His, Ser, Trp ili Tyr umjesto Asn na položaju 434; i aminokiselinske zamjene His ili Phe umjesto Tyr na položaju 436 prema EU numeriranju.
7. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačeno time što mu domena za vezanje na ljudski FcRn sadrži najmanje jednu aminokiselinu koja se bira između: Met na aminokiselinskom položaju 237; Ala na aminokiselinskom položaju 238; Lys na aminokiselinskom položaju 239; Ile na aminokiselinskom položaju 248; Ala, Phe, Ile, Met, Gln, Ser, Val, Trp ili Tyr na aminokiselinskom položaju250; Phe, Trp ili Tyr na aminokiselinskom položaju 252; Thr na aminokiselinskom položaju 254; Glu na aminokiselinskom položaju 255; Asp, Glu ili Gln na aminokiselinskom položaju 256; Ala, Gly, Ile, Leu, Met, Asn, Ser, Thr ili Val na aminokiselinskom položaju 257; His na aminokiselinskom položaju 258; Ala na aminokiselinskom položaju 265; Phe na aminokiselinskom položaju 270; Ala ili Glu na aminokiselinskom položaju 286; His na aminokiselinskom položaju 289; Ala na aminokiselinskom položaju 297; Gly na aminokiselinskom položaju 298; Ala na aminokiselinskom položaju 303; Ala na aminokiselinskom položaju 305; Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Val, Trp ili Tyr na aminokiselinskom položaju 307; Ala, Phe, Ile, Leu, Met, Pro, Gln ili Thr na aminokiselinskom položaju 308; Ala, Asp, Glu, Pro ili Arg na aminokiselinskom položaju 309; Ala, His ili Ile na aminokiselinskom položaju 311; Ala ili His na aminokiselinskom položaju 312; Lys ili Arg na aminokiselinskom položaju 314; Ala ili His na aminokiselinskom položaju 315; Ala na aminokiselinskom položaju 317; Gly na aminokiselinskom položaju 325; Val na aminokiselinskom položaju 332; Leu na aminokiselinskom položaju 334; His na aminokiselinskom položaju 360; Ala na aminokiselinskom položaju 376; Ala na aminokiselinskom položaju 380; Ala na aminokiselinskom položaju 382; Ala na aminokiselinskom položaju 384; Asp ili His na aminokiselinskom položaju 385; Pro na aminokiselinskom položaju 386; Glu na aminokiselinskom položaju 387; Ala ili Ser na aminokiselinskom položaju 389; Ala na aminokiselinskom položaju 424; Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Asn, Pro, Gln, Ser, Thr, Val, Trp ili Tyr na aminokiselinskom položaju 428; Lys na aminokiselinskom položaju 433; Ala, Phe, His, Ser, Trp ili Tyr na aminokiselinskom položaju 434; i His ili Phe kao aminokiselina na položaju 436 (EU numeriranje) u Fc domeni ljudskog IgG1, IgG2, IgG3 ili IgG4.
8. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačeno time što ima antagonističku aktivnost.
9. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačeno time što se veže na membranski antigen ili topljivi antigen.
10. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačeno time što se protutijelo bira između kimernog protutijela, humaniziranog protutijela ili ljudskog protutijela.
11. Farmaceutski pripravak, naznačen time što sadrži protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 10.
12. Postupak proizvodnje protutijela, naznačen time što obuhvaća korake: (a) odabir protutijela s većom aktivnošću vezanja na ljudski FcRn kod pH 7,0 nego prije izmjene najmanje jedne aminokiseline u domeni za vezanje na ljudski FcRn protutijela s aktivnošću vezanja na ljudski FcRn kod pH 5,5; (b) izmjena najmanje jedne aminokiseline u domeni za vezanje na antigen protutijela i odabira protutijela s većom aktivnošću vezanja na antigen kod pH 7,0 nego kod pH 5,5; (c) dobivanje gena koji kodira protutijelo u kojem su domena za vezanje na ljudski FcRn i domena za vezanje na antigen dobivene u (a) i (b) međusobno povezane; i (d) proizvodnja protutijela uz upotrebu gena dobivenog u (c).
13. Postupak proizvodnje protutijela, naznačen time što obuhvaća korake: (a) odabir protutijela s većom aktivnošću vezanja na ljudski FcRn kod pH 7,0 nego prije izmjene najmanje jedne aminokiseline u domeni za vezanje na ljudski FcRn protutijela s aktivnošću vezanja na ljudski FcRn kod pH 5,5; (b) odabir protutijela s većom aktivnošću vezanja na antigen kod pH 7,0 nego kod pH 5,5; (c) dobivanje gena koji kodira protutijelo u kojem su domena za vezanje na ljudski FcRn i domena za vezanje na antigen dobivene u (a) i (b) međusobno povezane; i (d) proizvodnja protutijela uz upotrebu gena dobivenog u (c).
14. Postupak probiranja protutijela, naznačen time što obuhvaća korake: (a) odabir protutijela s većom aktivnošću vezanja na ljudski FcRn kod pH 7,0 nego prije izmjene najmanje jedne aminokiseline u domeni za vezanje na ljudski FcRn protutijela s aktivnošću vezanja na ljudski FcRn kod pH 5,5; i (b) izmjena najmanje jedne aminokiseline u domeni za vezanje na antigen protutijela i odabira protutijela s većom aktivnošću vezanja na antigen kod pH 7,0 nego kod pH 5,5.
HRP20171080TT 2010-03-30 2017-07-14 Protutijela s modificiranim affinitetom za fcrn koja potiču uklanjanje antigena HRP20171080T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010079667 2010-03-30
JP2010250830 2010-11-09
EP11714860.1A EP2552955B1 (en) 2010-03-30 2011-03-30 Antibodies with modified affinity to fcrn that promote antigen clearance
PCT/JP2011/001888 WO2011122011A2 (en) 2010-03-30 2011-03-30 Antibodies with modified affinity to fcrn that promote antigen clearance

Publications (1)

Publication Number Publication Date
HRP20171080T1 true HRP20171080T1 (hr) 2017-10-06

Family

ID=44260244

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171080TT HRP20171080T1 (hr) 2010-03-30 2017-07-14 Protutijela s modificiranim affinitetom za fcrn koja potiču uklanjanje antigena

Country Status (19)

Country Link
US (5) US20130131319A1 (hr)
EP (3) EP2552955B1 (hr)
JP (7) JP5415624B2 (hr)
KR (4) KR101974794B1 (hr)
CN (2) CN113307868A (hr)
AU (1) AU2011233390B2 (hr)
BR (1) BR112012024710B1 (hr)
DK (1) DK2552955T3 (hr)
ES (1) ES2633597T3 (hr)
HR (1) HRP20171080T1 (hr)
HU (1) HUE033812T2 (hr)
LT (1) LT2552955T (hr)
MX (1) MX2012011338A (hr)
PL (1) PL2552955T3 (hr)
PT (1) PT2552955T (hr)
SG (2) SG10201703798YA (hr)
SI (1) SI2552955T1 (hr)
TW (2) TWI667346B (hr)
WO (1) WO2011122011A2 (hr)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) * 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
TWI464262B (zh) 2007-09-26 2014-12-11 中外製藥股份有限公司 抗體固定區的變異
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI761912B (zh) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
AU2012233313C1 (en) * 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
KR102049122B1 (ko) 2011-06-30 2019-11-26 추가이 세이야쿠 가부시키가이샤 헤테로이량화 폴리펩티드
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
RU2722829C9 (ru) 2011-09-30 2020-09-22 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, индуцирующая иммунный ответ на антиген-мишень
SG11201401101XA (en) * 2011-09-30 2014-08-28 Chugai Pharmaceutical Co Ltd Antigen-binding molecule for promoting loss of antigens
WO2013047748A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CN104080909A (zh) * 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
WO2013120929A1 (en) 2012-02-15 2013-08-22 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
TW202015731A (zh) * 2012-02-24 2020-05-01 日商中外製藥股份有限公司 經FcγRIIB促進抗原消失之抗原結合分子
US9801362B2 (en) 2012-03-16 2017-10-31 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
MY172730A (en) 2012-03-16 2019-12-11 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
CN104302170B (zh) * 2012-03-16 2016-09-28 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
MX360368B (es) * 2012-04-27 2018-10-29 Bioatla Llc Regiones de anticuerpo modificado y sus usos.
EP3892638A1 (en) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
EP3795215A1 (en) * 2012-05-30 2021-03-24 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
CN113831406A (zh) 2012-08-24 2021-12-24 中外制药株式会社 FcγRIIb特异性Fc区变体
DK2940135T5 (da) 2012-12-27 2021-09-20 Chugai Pharmaceutical Co Ltd Heterodimeriseret polypeptid
GB201302878D0 (en) * 2013-02-19 2013-04-03 Argen X Bv Modified igG molecules
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
SG11201508911PA (en) 2013-04-29 2015-11-27 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
KR102441231B1 (ko) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 폴리펩티드 이종 다량체의 제조방법
MX2016003617A (es) 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
CN105940107B (zh) 2013-11-11 2021-06-15 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
MX2016007312A (es) 2013-12-04 2017-01-13 Chugai Pharmaceutical Co Ltd Moleculas de union al antigeno, cuya actividad de union al antigeno varia de acuerdo con la concentracion de los compuestos y bibliotecas de dichas moleculas.
CA2932364A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
WO2015175874A2 (en) * 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
CN106459191B (zh) * 2014-06-12 2021-12-10 豪夫迈·罗氏有限公司 选择具有修饰的FcRn相互作用的抗体的方法
FR3024453B1 (fr) * 2014-08-01 2018-06-29 Lab Francais Du Fractionnement Procede de production de variants ayant un fc presentant une sialylation amelioree
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
MX2017005148A (es) 2014-11-06 2017-08-08 Hoffmann La Roche Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
MX2017005150A (es) * 2014-11-06 2017-08-08 Hoffmann La Roche Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
US10307480B2 (en) 2014-11-06 2019-06-04 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
PE20171111A1 (es) 2014-12-19 2017-08-07 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso
TW201809008A (zh) 2014-12-19 2018-03-16 日商中外製藥股份有限公司 抗ｃ５抗體及使用方法
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
AU2016224409B2 (en) 2015-02-27 2021-01-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
CN113896789A (zh) 2015-09-15 2022-01-07 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
KR20230079500A (ko) 2015-09-18 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8에 결합하는 항체 및 그의 사용
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
WO2017214170A2 (en) * 2016-06-06 2017-12-14 City Of Hope Baff-r antibodies and uses thereof
IL309975A (en) 2016-06-14 2024-03-01 Regeneron Pharma Antibodies against C5 and their uses
US11858980B2 (en) 2016-08-02 2024-01-02 Visterra, Inc. Engineered polypeptides and uses thereof
WO2018025982A1 (ja) 2016-08-05 2018-02-08 中外製薬株式会社 Ｉｌ－８関連疾患の治療用又は予防用組成物
US10669344B2 (en) 2016-08-12 2020-06-02 Janssen Biotech, Inc. Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3526240A1 (en) 2016-10-14 2019-08-21 Xencor, Inc. Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
HUE061656T2 (hu) 2017-01-06 2023-07-28 Scholar Rock Inc Metabolikus betegségek kezelése a miosztatin aktiválás gátlásával
JP6974500B2 (ja) * 2017-01-13 2021-12-01 ハンクス バイオファーマシューティクス，インコーポレイテッド ＦｃＲｎに対するＩｇＧ様抗体の結合親和性を増加し、その血清半減期を延長させる方法
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
SG11201801401UA (en) 2017-01-31 2018-09-27 Chugai Pharmaceutical Co Ltd A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
AU2018218345A1 (en) * 2017-02-10 2019-08-29 Genmab B.V. Polypeptide variants and uses thereof
PL3583120T3 (pl) 2017-02-17 2023-01-09 Denali Therapeutics Inc. Konstruowane polipeptydy wiążące receptory transferyny
CA3120566C (en) * 2017-04-07 2023-12-12 Kookmin University Industry Academy Cooperation Foundation Antibody fc variants for increased blood half-life
EP3612560A1 (en) 2017-04-21 2020-02-26 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
CN110785185A (zh) * 2017-06-05 2020-02-11 詹森生物科技公司 具有非对称ch2-ch3区突变的工程化多特异性抗体和其他多聚体蛋白
CN111132733A (zh) 2017-06-30 2020-05-08 Xencor股份有限公司 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
AU2018306612C1 (en) 2017-07-27 2023-11-09 Alexion Pharmaceuticals, Inc. High concentration anti-C5 antibody formulations
US11059892B2 (en) 2017-08-11 2021-07-13 Research Development Foundation Engineered antibody Fc variants for enhanced serum half life
BR112020006434A2 (pt) 2017-10-06 2020-11-03 Prothena Biosciences Limited anticorpos anti-transtirretina
US20210190764A1 (en) * 2017-10-20 2021-06-24 Chugai Seiyaku Kabushiki Kaisha Method for measuring cellular uptake of molecules
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
AU2018361957B2 (en) 2017-10-31 2023-05-25 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
BR112020010483A2 (pt) 2017-11-29 2020-10-20 Prothena Biosciences Limited formulação liofilizada de um anticorpo monoclonal contra transtirretina
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137
CA3083113A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
AU2019214865A1 (en) * 2018-02-02 2020-09-17 OncoC4, Inc. Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
WO2019152413A1 (en) * 2018-02-02 2019-08-08 Oncoimmune, Inc. Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
CN116327926A (zh) 2018-03-15 2023-06-27 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
TWI829679B (zh) * 2018-03-26 2024-01-21 美商再生元醫藥公司 用於測試治療藥劑之人類化囓齒動物
SG11202010125VA (en) * 2018-04-13 2020-11-27 Chugai Pharmaceutical Co Ltd Anti-complement component antibodies and methods of use
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
GB201809341D0 (en) * 2018-06-07 2018-07-25 Ucb Biopharma Sprl Multi-domain proteins with increased native state colloidal stability
TW202020158A (zh) 2018-06-26 2020-06-01 日商協和麒麟股份有限公司 與細胞黏著分子3 結合之抗體
EP3816291A4 (en) 2018-06-26 2022-03-16 Kyowa Kirin Co., Ltd. CHONDROITIN SULFATE PROTEOGLYCAN-5 BINDING ANTIBODIES
KR20210034032A (ko) 2018-07-19 2021-03-29 리제너론 파아마슈티컬스, 인크. 이중특이적 항-BCMA x 항-CD3 항체 및 이의 용도
KR20200033348A (ko) 2018-08-01 2020-03-27 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
EA202190451A1 (ru) 2018-08-10 2021-07-13 Чугаи Сейяку Кабусики Кайся Анти-cd137 антигенсвязывающие молекулы и их применение
US11377477B2 (en) 2018-10-12 2022-07-05 Xencor, Inc. PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
CA3118397A1 (en) * 2018-11-01 2020-05-07 Shandong Newtime Pharmaceutical Co., Ltd. Bispecific antibody targeting cd3 and bcma, and uses thereof
WO2020132230A2 (en) 2018-12-20 2020-06-25 Genentech, Inc. Modified antibody fcs and methods of use
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
WO2020189748A1 (ja) 2019-03-19 2020-09-24 中外製薬株式会社 Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
KR20210149779A (ko) 2019-04-10 2021-12-09 추가이 세이야쿠 가부시키가이샤 Fc 영역 개변 항체의 정제 방법
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
EP3980127A1 (en) * 2019-06-06 2022-04-13 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
WO2020247878A1 (en) * 2019-06-06 2020-12-10 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
MX2021015095A (es) * 2019-06-07 2022-03-22 Mythic Therapeutics Inc Construcciones de proteínas de unión a antígenos y usos de estos.
EP3996817A1 (en) * 2019-07-08 2022-05-18 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
KR20220053577A (ko) * 2019-07-30 2022-04-29 마이틱 테라퓨틱스, 인크. 항원 결합 단백질 작제물 및 이의 용도
AU2020330307A1 (en) * 2019-08-12 2022-03-17 CSL Innovation Pty Ltd Complement C2 binding proteins and uses thereof
CA3157028A1 (en) * 2019-10-04 2021-04-08 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
PE20221661A1 (es) 2019-12-18 2022-10-26 Hoffmann La Roche Anticuerpos anti-ccl2 biespecificos
IL294226A (en) 2019-12-27 2022-08-01 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibodies and their use
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
CN115038721A (zh) * 2020-01-29 2022-09-09 高丽大学校产学协力团 pH敏感性Fc变体
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
US20230416371A1 (en) 2020-08-28 2023-12-28 Chugai Seiyaku Kabushiki Kaisha Heterodimer fc polypeptide
JP2024502863A (ja) 2021-01-13 2024-01-23 ビステラ， インコーポレイテッド ヒト化補体５ａ受容体１抗体及びその使用方法
EP4355775A1 (en) 2021-06-18 2024-04-24 F. Hoffmann-La Roche AG Bispecific anti-ccl2 antibodies
KR20240024213A (ko) 2021-06-25 2024-02-23 추가이 세이야쿠 가부시키가이샤 항ctla-4 항체
WO2022270612A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体の使用
AU2022328727A1 (en) * 2021-08-20 2024-03-07 The Government Of The United States, As Represented By The Secretary Of The Army IgA MONOCLONAL ANTIBODIES FOR TREATING FLAVIVIRUS INFECTION

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS63149900A (ja) 1986-12-15 1988-06-22 Toshiba Corp 半導体メモリ
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methoden zur Herstellung humanisierter Antikörper
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
WO1995015393A1 (fr) 1993-12-03 1995-06-08 Asahi Kasei Kogyo Kabushiki Kaisha Nouveau vecteur de detection d'expression
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP0962467A4 (en) 1996-09-26 2002-10-30 Chugai Pharmaceutical Co Ltd ANTIBODIES AGAINST HUMAN PARATHORMON RELATED PEPTIDES
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
ES2651952T3 (es) 2000-10-06 2018-01-30 Kyowa Hakko Kirin Co., Ltd. Células que producen unas composiciones de anticuerpo
WO2002032925A2 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
WO2003105757A2 (en) 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
CA2545603A1 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
BRPI0506771A (pt) 2004-01-12 2007-05-22 Applied Molecular Evolution anticorpo, e, composição farmacêutica
DE102004032634A1 (de) 2004-07-06 2006-02-16 Sms Demag Ag Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk
ES2426816T3 (es) 2004-08-04 2013-10-25 Mentrik Biotech, Llc Regiones Fc variantes
CN101052654A (zh) 2004-08-19 2007-10-10 健泰科生物技术公司 具有改变的效应子功能的多肽变体
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP1817340B1 (en) 2004-11-12 2012-05-16 Xencor, Inc. Fc variants with altered binding to fcrn
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
AU2005323025A1 (en) 2004-12-31 2006-07-13 Biogen Idec Ma Inc. Polypeptides that bind BR3 and uses thereof
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
EP2021463B1 (en) 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
LT2808343T (lt) 2007-12-26 2019-09-10 Xencor Inc. Fc variantai su pakitusiu prisijungimu prie fcrn
US20110183861A1 (en) * 2008-01-29 2011-07-28 Ablynn N.V. Methods to stabilize proteins and polypeptides
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
TWI564021B (zh) * 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
EP2282770B1 (en) 2008-06-04 2018-03-07 MacroGenics, Inc. Antibodies with altered binding to fcrn and methods of using same
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5028372B2 (ja) 2008-09-26 2012-09-19 京セラドキュメントソリューションズ株式会社 画像処理装置、画像処理方法及び画像処理プログラム
JP5913980B2 (ja) * 2008-10-14 2016-05-11 ジェネンテック， インコーポレイテッド 免疫グロブリン変異体及びその用途
CA2700030C (en) 2009-04-16 2019-11-05 Accenture Global Services Gmbh Touchpoint customization system
LT3053932T (lt) * 2010-02-19 2020-11-10 Xencor, Inc. Nauji ctla4-ig imunoadhezinai
CN102844332B (zh) 2010-03-11 2015-08-19 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
JP7037885B2 (ja) 2014-06-30 2022-03-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ｐＨ依存性抗原結合を示す抗ＴＮＦａ抗体

Also Published As

Publication number Publication date
CN102918057A (zh) 2013-02-06
SG10201703798YA (en) 2017-06-29
US20170002066A1 (en) 2017-01-05
SI2552955T1 (sl) 2017-08-31
US20170002080A1 (en) 2017-01-05
TW201700499A (zh) 2017-01-01
JP6850317B2 (ja) 2021-03-31
TWI667346B (zh) 2019-08-01
US20130131319A1 (en) 2013-05-23
JP2016145222A (ja) 2016-08-12
EP3181581A1 (en) 2017-06-21
US20160244526A1 (en) 2016-08-25
WO2011122011A2 (en) 2011-10-06
AU2011233390A1 (en) 2012-11-08
BR112012024710A2 (pt) 2021-04-27
JP5913243B2 (ja) 2016-04-27
EP3702368A1 (en) 2020-09-02
EP2552955B1 (en) 2017-05-03
JP2019178134A (ja) 2019-10-17
AU2011233390B2 (en) 2015-08-20
PL2552955T3 (pl) 2017-12-29
CN102918057B (zh) 2021-06-01
KR102269707B1 (ko) 2021-06-25
JP6518222B2 (ja) 2019-05-22
BR112012024710A8 (pt) 2021-06-08
JP2023022203A (ja) 2023-02-14
WO2011122011A3 (en) 2012-01-05
DK2552955T3 (en) 2017-08-21
EP2552955A2 (en) 2013-02-06
SG184163A1 (en) 2012-10-30
JP5415624B2 (ja) 2014-02-12
KR20180019764A (ko) 2018-02-26
KR102468436B1 (ko) 2022-11-17
TWI667257B (zh) 2019-08-01
BR112012024710B1 (pt) 2022-06-07
CN113307868A (zh) 2021-08-27
JP6029252B2 (ja) 2016-11-24
PT2552955T (pt) 2017-07-12
TW201202419A (en) 2012-01-16
JP2013528354A (ja) 2013-07-11
US20170226206A1 (en) 2017-08-10
LT2552955T (lt) 2017-07-25
KR20130010002A (ko) 2013-01-24
MX2012011338A (es) 2012-11-30
KR101974794B1 (ko) 2019-05-02
ES2633597T3 (es) 2017-09-22
JP2017036318A (ja) 2017-02-16
KR20190047111A (ko) 2019-05-07
KR101831464B1 (ko) 2018-02-22
KR20210079407A (ko) 2021-06-29
JP2014065708A (ja) 2014-04-17
HUE033812T2 (en) 2018-01-29
JP7186813B2 (ja) 2022-12-09
JP2021091725A (ja) 2021-06-17

Similar Documents

Publication Publication Date Title
HRP20171080T1 (hr) Protutijela s modificiranim affinitetom za fcrn koja potiču uklanjanje antigena
HRP20200189T1 (hr) Anti-tigit antitijela, anti-pvrig antitijela i njihove kombinacije
HRP20191342T1 (hr) Anti-phf-tau antitijela i njihove upotrebe
JP7308892B2 (ja) Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
RU2014117504A (ru) Антигенсвязывающая молекула, индуцирующая иммунный ответ на антиген-мишень
HRP20201191T1 (hr) Mutirani multispecifični fab fragmenti antitijela
CN104640879B (zh) Il-18结合分子
HRP20191341T1 (hr) Protutijela koja vežu ljudski cgrp receptor
RU2011135422A (ru) Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний
HRP20140760T1 (hr) Citotoksiäśni imunoglobulin
Wu et al. Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules
HRP20170254T1 (hr) Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
JP2017520575A5 (hr)
CA3061430A1 (en) Method of preparing ph-dependent antibodies
HRP20221088T1 (hr) Protutijela i postupci uporabe
RU2014117505A (ru) Антигенсвязывающая молекула для ускорения удаления антигенов
JP2012516158A5 (hr)
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
HRP20090326T1 (hr) Sintetičke domene imunoglobulina sa vezujućim svojstvima izgrađenim u područjima molekule različitim od komplementarno određujućih područja
JP2020510658A (ja) 操作されたヘテロ二量体タンパク質
RU2018137110A (ru) Антитела против psma и их применение
CN108064245A (zh) 抗Tyro3抗体及其用途
CN109715661A (zh) 抗干扰素-γ的抗体及其应用
Lee et al. A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions
CN111320693A (zh) 抗EphA4抗体